Monitor for S-3 filing in coming weeks which could enable resale and increase share float; assess whether the clinical milestone met is material relative to trial endpoints. The extended cash runway reduces near-term financing risk, but no clinical data was released — evaluate upcoming trial readouts for value inflection.
Price Chart
Executive Summary
Lyell Immunopharma closed an additional $50 million tranche of its private placement, bringing total proceeds to $100 million, following a clinical milestone in its ronde-cel PiNACLE trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer to lead financial strategy amid this capital raise.
Key Financial Metrics
Key Facts
- Lyell closed an additional $50 million tranche of a $100 million private placement after achieving a clinical milestone in the ronde-cel PiNACLE trial.
- Total gross proceeds from the private placement are now $100 million, priced at $25.61 per share.
- Cash runway is expected to extend into Q2 2027.
- Smital Shah was appointed Chief Financial and Business Officer, effective March 9, 2026, bringing extensive biopharma finance and strategy experience.
- The securities were sold in a private placement without registration, with investors receiving Form S-3 resale registration rights.
Financial Impact
$50 million in new capital raised at $25.61/share, doubling prior tranche; total $100 million private placement now complete.
Risk Factors
- Dilution from $50 million in new shares issued, though pricing was at a fixed $25.61 (current stock price not disclosed).
- Forward-looking statements dominate; the clinical milestone is not described in detail, so its materiality is uncertain.
- Private placement may lead to increased share volatility once resale registration becomes effective.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251756 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.26 (−40.22%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.26 (−27.88%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.26 (−25.56%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.26 (−31.41%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.26 (−24.78%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.26 (−22.64%) |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.26 (−59.06%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.26 (−61.16%) |
Apr 3, 2026 26w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.26 (−57.31%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.26 (−56.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access